Chowdhury S

Center for Infectious Disease Research

2
EM Publications
18
h-index
(939 citations, 45 total works)

Research Topics

Ion channel regulation and function (15) Supramolecular Chemistry and Complexes (8) Tuberculosis Research and Epidemiology (6) Neuroscience and Neuropharmacology Research (6) Cholinesterase and Neurodegenerative Diseases (6)

Erythromelalgia Publications

Discovery of novel cyclopentane carboxylic acids as potent and selective inhibitors of Na1.7.

Sun S, Chowdhury S, Hemeon I, Hasan A, Wilson MS , et al.
Bioorganic & medicinal chemistry letters

Discovery efforts leading to the identification of cyclopentane carboxylic acid 31, a potent inhibitor of Na1.7 that showed high selectivity over Na1.5 and exhibited robust analgesic effects in an inherited erythromelalgia (IEM) transgenic mouse assay, are described herein. Key design elements that culminated in the discovery of 31 include exploration of proline substituents, replacement of the proline warhead with cyclopentane carboxylic acid, that led to significantly boosted Na1.7 potency, and replacement of the metabolically labile adamantane motif with the 2,6-dichlorobenzyl substituted piperidine system, that addressed metabolic instability and led to a significant improvement in PK.

Selective Na1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic Pain.

Bankar G, Goodchild SJ, Howard S, Nelkenbrecher K, Waldbrook M , et al.
Cell reports

Selective block of Na1.7 promises to produce non-narcotic analgesic activity without motor or cognitive impairment. Several Na1.7-selective blockers have been reported, but efficacy in animal pain models required high multiples of the IC for channel block. Here, we report a target engagement assay using transgenic mice that has enabled the development of a second generation of selective Nav1.7 inhibitors that show robust analgesic activity in inflammatory and neuropathic pain models at low multiples of the IC. Like earlier arylsulfonamides, these newer acylsulfonamides target a binding site on the surface of voltage sensor domain 4 to achieve high selectivity among sodium channel isoforms and steeply state-dependent block. The improved efficacy correlates with very slow dissociation from the target channel. Chronic dosing increases compound potency about 10-fold, possibly due to reversal of sensitization arising during chronic injury, and provides efficacy that persists long after the compound has cleared from plasma.